{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T12:55:30Z","timestamp":1770987330522,"version":"3.50.1"},"reference-count":35,"publisher":"Hindawi Limited","issue":"4","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":3105,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1111\/j.1742-1241.2007.01321.x","type":"journal-article","created":{"date-parts":[[2007,3,2]],"date-time":"2007-03-02T23:14:32Z","timestamp":1172877272000},"page":"653-662","source":"Crossref","is-referenced-by-count":35,"title":["Paliperidone: quo vadis?"],"prefix":"10.1155","volume":"61","author":[{"given":"L.","family":"Citrome","sequence":"first","affiliation":[]}],"member":"98","published-online":{"date-parts":[[2007,3,2]]},"reference":[{"key":"10.1111\/j.1742-1241.2007.01321.x-BIB1|cit1","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1001\/archpsyc.60.6.553","article-title":"A meta-analysis of the efficacy of second-generation antipsychotics","volume":"60","author":"Davis","year":"2003","journal-title":"Arch Gen Psychiatry"},{"key":"10.1111\/j.1742-1241.2007.01321.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1176\/ajp.2006.163.4.600","article-title":"Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment","volume":"163","author":"McEvoy","year":"2006","journal-title":"Am J Psychiatry"},{"key":"10.1111\/j.1742-1241.2007.01321.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/BF02245444","article-title":"Regional brain distribution of risperidone and its active metabolite 9-hydroxy-risperidone in the rat","volume":"114","author":"Van Beijsterveldt","year":"1994","journal-title":"Psychopharmacology (Berl)"},{"issue":"Suppl. 5","key":"10.1111\/j.1742-1241.2007.01321.x-BIB4|cit4","first-page":"5","article-title":"Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity","volume":"55","author":"Leysen","year":"1994","journal-title":"J Clin Psychiatry"},{"issue":"Suppl. 11","key":"10.1111\/j.1742-1241.2007.01321.x-BIB5|cit5","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1017\/S1092852900025086","article-title":"Atypical antipsychotics: matching receptor profile to individual patient's clinical profile","volume":"9","author":"Shayegan","year":"2004","journal-title":"CNS Spectr"},{"key":"10.1111\/j.1742-1241.2007.01321.x-BIB6|cit6","unstructured":"Janssen LP. Invega (Paliperidone) Extended-Release Tablets http:\/\/www.invega.com\/active\/janus\/en_US\/assets\/common\/company\/pi\/invega.pdf"},{"key":"10.1111\/j.1742-1241.2007.01321.x-BIB7|cit7","volume-title":"Poster I-90 Presented at the 46th Annual Meeting of the NCDEU","author":"Thyssen","year":"2006"},{"key":"10.1111\/j.1742-1241.2007.01321.x-BIB8|cit8","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1097\/00007691-200312000-00003","article-title":"Intra- and interindividual variations in steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone in schizophrenic patients treated chronically with various doses of risperidone","volume":"25","author":"Aravagiri","year":"2003","journal-title":"Ther Drug Monit"},{"key":"10.1111\/j.1742-1241.2007.01321.x-BIB9|cit9","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1007\/s002130000576","article-title":"Relationship between plasma risperidone and 9-hydroxyrisperidone concentrations and clinical response in patients with schizophrenia","volume":"153","author":"Spina","year":"2001","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1111\/j.1742-1241.2007.01321.x-BIB10|cit10","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1097\/00007691-200008000-00019","article-title":"Plasma concentrations of risperidone and 9-hydroxyrisperidone: effect of comedication with carbamazepine or valproate","volume":"22","author":"Spina","year":"2000","journal-title":"Ther Drug Monit"},{"key":"10.1111\/j.1742-1241.2007.01321.x-BIB11|cit11","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1176\/appi.ajp.162.5.1010","article-title":"Predominant role of the 9-hydroxy metabolite of risperidone in elevating blood prolactin levels","volume":"162","author":"Knegtering","year":"2005","journal-title":"Am J Psychiatry"},{"key":"10.1111\/j.1742-1241.2007.01321.x-BIB12|cit12","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1007\/BF02244986","article-title":"Plasma protein binding of risperidone and its distribution in blood","volume":"114","author":"Mannens","year":"1994","journal-title":"Psychopharmacology (Berl)"},{"issue":"Suppl. 5","key":"10.1111\/j.1742-1241.2007.01321.x-BIB13|cit13","first-page":"13","article-title":"The pharmacokinetics of risperidone in humans: a summary","volume":"55","author":"Heykants","year":"1994","journal-title":"J Clin Psychiatry"},{"key":"10.1111\/j.1742-1241.2007.01321.x-BIB14|cit14","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1185\/030079906X132613","article-title":"Clinical spectrum of the osmotic-controlled release oral delivery system (OROS), an advanced oral delivery form","volume":"22","author":"Conley","year":"2006","journal-title":"Curr Med Res Opin"},{"key":"10.1111\/j.1742-1241.2007.01321.x-BIB15|cit15","doi-asserted-by":"crossref","first-page":"477","DOI":"10.7326\/0003-4819-141-6-200409210-00109","article-title":"Clinical trial registration: a statement from the International Committee of Medical Journal Editors","volume":"141","author":"De Angelis","year":"2004","journal-title":"Ann Intern Med"},{"key":"10.1111\/j.1742-1241.2007.01321.x-BIB16|cit16","unstructured":"International Committee of Medical Journal Editors Uniform Requirements for Manuscripts Submitted to Biomedical Journals: Writing and Editing for Biomedical Publication http:\/\/www.icmje.org\/icmje.pdf"},{"key":"10.1111\/j.1742-1241.2007.01321.x-BIB17|cit17","article-title":"Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial","author":"Kane","year":"2006","journal-title":"Schizophr Res"},{"key":"10.1111\/j.1742-1241.2007.01321.x-BIB18|cit18","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1111\/j.1742-1241.2006.01044.x","article-title":"Schizophrenia, Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) and number needed to treat: how can CATIE inform clinicians?","volume":"60","author":"Citrome","year":"2006","journal-title":"Int J Clin Pract"},{"key":"10.1111\/j.1742-1241.2007.01321.x-BIB19|cit19","volume-title":"Poster I-75 Presented at the 46th Annual Meeting of the NCDEU","author":"Marder","year":"2006"},{"key":"10.1111\/j.1742-1241.2007.01321.x-BIB20|cit20","volume-title":"Poster NR338 Presented at the 159th Annual Meeting of the American Psychiatric Association","author":"Davidson","year":"2006"},{"key":"10.1111\/j.1742-1241.2007.01321.x-BIB21|cit21","volume-title":"Poster NR441 Presented at the 159th Annual Meeting of the American Psychiatric Association","author":"Kramer","year":"2006"},{"key":"10.1111\/j.1742-1241.2007.01321.x-BIB22|cit22","volume-title":"Poster P.1.b.013 Presented at the 19th Congress of the European College of Neuropsychopharmacology","author":"Luthringer","year":"2006"},{"key":"10.1111\/j.1742-1241.2007.01321.x-BIB23|cit23","volume-title":"Poster P03.174 Presented at the 25th Congress of the Collegium Internationale Neuro-psychopharmacologicum","author":"Kramer","year":"2006"},{"key":"10.1111\/j.1742-1241.2007.01321.x-BIB24|cit24","volume-title":"Poster P03.204 Presented at the 25th Congress of the Collegium Internationale Neuro-psychopharmacologicum","author":"Meyer","year":"2006"},{"key":"10.1111\/j.1742-1241.2007.01321.x-BIB25|cit25","volume-title":"Poster P01.224 Presented at the 25th Congress of the Collegium Internationale Neuro-psychopharmacologicum","author":"Kostic","year":"2006"},{"key":"10.1111\/j.1742-1241.2007.01321.x-BIB26|cit26","volume-title":"Poster NR345 Presented at the 159th Annual Meeting of the American Psychiatric Association","author":"Emsley","year":"2006"},{"key":"10.1111\/j.1742-1241.2007.01321.x-BIB27|cit27","volume-title":"Poster NR342 Presented at the 159th Annual Meeting of the American Psychiatric Association","author":"Dirks","year":"2006"},{"key":"10.1111\/j.1742-1241.2007.01321.x-BIB28|cit28","volume-title":"Poster P01.201 Presented at the 25th Congress of the Collegium Internationale Neuro-psychopharmacologicum","author":"Kramer","year":"2006"},{"key":"10.1111\/j.1742-1241.2007.01321.x-BIB29|cit29","first-page":"118","article-title":"Paliperidone: long-acting antipsychotic can be taken once daily","volume":"5","author":"Simpson","year":"2006","journal-title":"Curr Psychiatry"},{"key":"10.1111\/j.1742-1241.2007.01321.x-BIB30|cit30","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1080\/10673220216279","article-title":"Optimal dosing of atypical antipsychotics in adults: a review of the current evidence","volume":"10","author":"Citrome","year":"2002","journal-title":"Harv Rev Psychiatry"},{"key":"10.1111\/j.1742-1241.2007.01321.x-BIB31|cit31","unstructured":"Janssen LP. Risperdal (Risperidone) Tablets\/Oral Solution. Risperdal M-Tab (Risperidone) Orally Disintegrating Tablets http:\/\/www.risperdal.com\/active\/janus\/en_US\/assets\/common\/company\/pi\/risperdal.pdf"},{"key":"10.1111\/j.1742-1241.2007.01321.x-BIB32|cit32","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1097\/01.jcp.0000169623.30196.b9","article-title":"Dosing of second-generation antipsychotic medication in a state hospital system","volume":"25","author":"Citrome","year":"2005","journal-title":"J Clin Psychopharmacol"},{"key":"10.1111\/j.1742-1241.2007.01321.x-BIB33|cit33","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1742-1241.2007.01321.x-BIB34|cit34","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1176\/ajp.2006.163.4.611","article-title":"Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic","volume":"163","author":"Stroup","year":"2006","journal-title":"Am J Psychiatry"},{"key":"10.1111\/j.1742-1241.2007.01321.x-BIB35|cit35","first-page":"B1","article-title":"A J&J copycat could extend old drugs\u2019 life","author":"Hensley","year":"2006","journal-title":"Wall St J"}],"container-title":["International Journal of Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1742-1241.2007.01321.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1742-1241.2007.01321.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T06:04:58Z","timestamp":1643349898000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1742-1241.2007.01321.x"}},"subtitle":["Paliperidone"],"short-title":[],"issued":{"date-parts":[[2007,3,2]]},"references-count":35,"journal-issue":{"issue":"4"},"URL":"https:\/\/doi.org\/10.1111\/j.1742-1241.2007.01321.x","relation":{},"ISSN":["1368-5031"],"issn-type":[{"value":"1368-5031","type":"print"}],"subject":[],"published":{"date-parts":[[2007,3,2]]}}}